This is a secured debt investment, not an acquisition, so the primary risk for SRXH is credit risk on a pre-revenue biotech. Monitor CERo's clinical trial progress for CER-1236 and its cash burn rate, as the loan matures in ~6 weeks (Oct 15, 2026) unless extended. The secured position and IP collateral provide some downside protection, but the near-term maturity creates a catalyst for either repayment, extension, or potential restructuring.
Price Chart
Executive Summary
SRX Global Inc. (SRXH) entered into a secured debt financing transaction with CERo Therapeutics Holdings, Inc. (CERO), acquiring a Consolidated Senior Secured Promissory Note consolidating $5.67M in prior notes and providing up to $6M in additional advances, for a maximum aggregate loan amount of $11.67M. The loan is secured by a first-priority security interest in all of CERO's assets, including its intellectual property and clinical-stage CER-1236 T-cell therapy program, as well as a pledge of 100% of the subsidiary's stock and an unconditional guaranty from the subsidiary. This is a debt investment by SRXH, not an acquisition, and represents a moderate deployment of capital into a high-risk, pre-revenue biotech company with a near-term maturity date of October 15, 2026, which can be extended by SRXH for up to four 30-day periods at its discretion.
Key Financial Metrics
Key Facts
- SRX Global acquired a senior secured promissory note from CERo Therapeutics Holdings with an aggregate maximum loan amount of $11,666,108.77.
- The note consolidates $5,666,108.77 in prior notes and provides for up to $6,000,000 in additional advances, with an initial advance of $775,665.00 funded on August 27, 2026.
- The loan matures on October 15, 2026, but SRXH can extend the maturity date for up to four consecutive 30-day periods at its discretion.
- The loan is secured by a first-priority security interest in substantially all assets of CERo Therapeutics, Inc., including key patents and the CER-1236 T-cell therapy program, plus a pledge of 100% of the subsidiary's stock and an unconditional guaranty.
- The note carries a 10% annual interest rate, increasing to 24.99% upon an event of default.
- CERo is a clinical-stage biotech with an ongoing Phase 1/1b CERTAIN-T trial for CER-1236 in hematologic malignancies; six patients have been treated with no dose-limiting toxicities observed in the most recent cohort.
Financial Impact
SRXH deployed $775,665 in initial cash and has committed up to $11.67M total in secured debt to CERo, a pre-revenue biotech. The investment yields 10% annual interest and is secured by CERo's IP and assets.
Risk Factors
- CERo is a pre-revenue clinical-stage biotech with no approved products, carrying high execution and financing risk.
- The loan matures on October 15, 2026, creating near-term liquidity pressure on CERo; if CERo cannot repay, SRXH may need to extend or exercise remedies against collateral.
- The value of the collateral (IP, clinical-stage assets) is highly uncertain and dependent on clinical trial outcomes and regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041250 |
| Exhibit: ex10-2.htm | 0001493152-26-041250 |
| Exhibit: ex10-3.htm | 0001493152-26-041250 |
| Exhibit: ex10-4.htm | 0001493152-26-041250 |
| Exhibit: ex99-1.htm | 0001493152-26-041250 |
| Document: form8-k.htm | 0001493152-26-041250 |
| Document: 0001493152-26-041250-index-headers.html | 0001493152-26-041250 |
| Document: 0001493152-26-041250-index.html | 0001493152-26-041250 |
| Document: 0001493152-26-041250.txt | 0001493152-26-041250 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $1.51 $1.60 | ▲ +5.96% | ▲ +6.62% | $1.61 (+6.62%) |
Sep 2, 2026 4w ago | 8-K | $1.56 $1.59 | ▲ +1.92% | ▲ +3.07% | $1.61 (+3.21%) |
Aug 28, 2026 5w ago | 8-K | $1.68 $1.59 | ▲ +5.65% | ▲ +5.51% | $1.61 (+4.17%) |
Aug 19, 2026 6w ago | 8-K | $1.87 $1.84 | ▼ −1.60% | ▼ −1.22% | $1.61 (−13.90%) |
Aug 4, 2026 8w ago | Press Release | $1.37 $1.84 | ▲ +34.31% | ▲ +34.41% | $1.61 (+17.52%) |
Aug 3, 2026 8w ago | Press Release | $1.44 $1.73 | ▲ +20.14% | ▲ +18.11% | $1.61 (+11.81%) |
Jul 30, 2026 9w ago | Press Release | $1.48 $1.43 | ▼ −3.38% | ▼ −7.00% | $1.61 (+8.78%) |
Jul 28, 2026 9w ago | 8-K | $1.48 $1.44 | ▲ +2.70% | ▲ +4.97% | $1.61 (−8.78%) |
Jul 16, 2026 11w ago | 8-K | $2.41 $1.80 | ▼ −25.31% | ▼ −23.64% | $1.61 (−33.20%) |
Jul 16, 2026 11w ago | Press Release | $2.41 $1.80 | ▼ −25.31% | ▼ −23.64% | $1.61 (−33.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access